Advertisement

T-Cell Therapies for EBV-Associated Malignancies

  • M. K. Brenner
  • C. Bollard
  • M. H. Huls
  • S. Gottschalk
  • H. E. Heslop
  • C. M. Rooney
Conference paper
Part of the Ernst Schering Research Foundation Workshop book series (SCHERING FOUND, volume 11)

8.6 Conclusion

At present, CTL are being used only in patients with advanced relapsed malignancies. As their safety and efficacy becomes better established we may expect their introduction earlier in the course of therapy where they may reduce the short- and long-term toxicities of standard radio- and chemotherapies. Further understanding of the ways in which immune evasion strategies can be counteracted in Hodgkin’s disease may also be applied to the many other human tumors that are potentially immunogenic and use similar immune evasion strategies.

Keywords

Lymphoblastoid Cell Line Latent Membrane Protein Immune Evasion Strategy Latent Membrane Protein Expression Virus Latent Membrane Protein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Anderson R, Macdonald I, Corbett T, Hacking G, Lowdell MW, Prentice HG (1997) Construction and biological characterization of an interleukin-12 fusion protein (Flexi-12): delivery to acute myeloid leukemic blasts using adeno-associated virus. Hum Gene Ther 8:1125–1135PubMedGoogle Scholar
  2. Bollard CM, Rossig C, Calonge MJ, et al. (2002) Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 99:3179–3187PubMedCrossRefGoogle Scholar
  3. Gahn B, Siller-Lopez F, Pirooz AD, et al. (2001) Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to the LMP2A-antigen: a potential treatment strategy for Epstein-Barr virus-positive Hodgkin’s lymphoma. Int J Cancer 93:706–713PubMedCrossRefGoogle Scholar
  4. Gottschalk S, Heslop HE, Rooney CM (2002) Treatment of Epstein-Barr virus-associated malignancies with specific T cells. Adv Cancer Res 84:175–201PubMedCrossRefGoogle Scholar
  5. Herbst H, Dallenback F, Hummel M, et al. (1991) Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci 88:4766–4770PubMedCrossRefGoogle Scholar
  6. Heslop H, Rooney C, Brenner M, et al. (2000) Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin’s disease. Hum Gene Ther 11:1465–1475PubMedCrossRefGoogle Scholar
  7. Heslop HE, Ng CYC, Li C, et al. (1996) Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 2:551–555PubMedCrossRefGoogle Scholar
  8. Hsu SM, Lin J, Xie SS, Hsu PL, Rich S (1993) Abundant expression of transforming growth factor-beta 1 and-beta 2 by Hodgkin’s Reed-Sternberg cells and by reactive T lymphocytes in Hodgkin’s disease. Hum Pathol 24:249–255PubMedCrossRefGoogle Scholar
  9. Lenardo M, Chan KM, Hornung F, et al. (1999) Mature T lymphocyte apoptosis-immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol 17:221–253PubMedCrossRefGoogle Scholar
  10. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL (1997) Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90(7):2541–2548PubMedGoogle Scholar
  11. Levitskaya J, Coram M, Levitsky V, et al. (1995) Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375:685–688PubMedCrossRefGoogle Scholar
  12. Lucey DR, Clerici M, Shearer GM (1996) Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 9(4):532–562PubMedGoogle Scholar
  13. Poppema S, Potters M, Visser L, van den Berg AM (1998) Immune escape mechanisms in Hodgkin’s disease. Ann Oncol 9(Suppl 5):S21–S24PubMedCrossRefGoogle Scholar
  14. Rickinson AB (1994) EBV infection and EBV-associated tumors. In: Minson AC, Neil JC, McRae MA (eds) Viruses and cancer. Cambridge University Press, Cambridge, pp 81–100Google Scholar
  15. Rooney CM, Smith CA, Ng CYC, et al. (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 345:9–13PubMedCrossRefGoogle Scholar
  16. Rooney CM, Smith CA, Ng CYC, et al. (1998) Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92:1549–1555PubMedGoogle Scholar
  17. Roskrow MA, Rooney CM, Heslop HE, et al. (1998 a) Administration of neomycin resistance gene marked EBV-specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin’s disease. Hum Gene Ther 9:1237–1250PubMedGoogle Scholar
  18. Roskrow MA, Suzuki N, Gan Y-J, et al. (1998b) EBV-specific cytotoxic T lymphocytes for the treatment of patients with EBV positive relapsed Hodgkin’s disease. Blood 91:2925–2934PubMedGoogle Scholar
  19. Skinnider BF, Mak TW (2002) The role of cytokines in classical Hodgkin lymphoma. Blood 99:4283–4297PubMedCrossRefGoogle Scholar
  20. Smith CA, Ng CYC, Heslop HE, et al. (1995) Production of genetically modified EBV-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother 4:73–79PubMedGoogle Scholar
  21. Voest EE, Kenyon BM, O’Reilly MS, Truitt G, D’Amato RJ, Folkman J (1995) Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87(8):581–586PubMedGoogle Scholar
  22. Wieser R, Attisano L, Wrana JL, Massague J (1993) Signaling activity of transforming growth factor beta type II receptors lacking specific domains in the cytoplasmic region. Mol Cell Biol 13:7239–7247PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • M. K. Brenner
    • 1
  • C. Bollard
    • 2
  • M. H. Huls
    • 3
  • S. Gottschalk
  • H. E. Heslop
    • 3
  • C. M. Rooney
    • 3
  1. 1.Section of Hematology-Oncology, Baylor College of MedicineCenter for Cell and Gene TherapyHoustonUSA
  2. 2.Center for Cell and Gene Therapy, Baylor College of MedicineThe Methodist Hospital and Texas Children’s HospitalHoustonUSA
  3. 3.Baylor College of MedicineCenter for Cell and Gene TherapyHoustonUSA

Personalised recommendations